

Oncology Drugs Market Size, Competitive Analysis, Size, Share, Trends, Growth and Forecast to 2026

Cancer is a chronic medical condition that involves an abnormal growth of cells. The abnormal growth of cells results in the formation of a tumor.

PORTLAND, OREGON, UNITED STATES, March 21, 2022 /EINPresswire.com/ -- The Japan [oncology drugs market](#) size was accounted for \$9,405 million in 2018, and is expected to reach \$14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.

According to the report published by Allied Market Research, Japan Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019–2026. The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.

Request Free Sample Report Now: <https://www.alliedmarketresearch.com/request-sample/5642>

Onkar Sumant, a Manager, Healthcare at Allied Market Research, stated, “Surge in prevalence of cancer is anticipated to significantly drive the growth of the Japan oncology drugs market. Furthermore, rise in geriatric population, increase in healthcare expenditure, and upsurge in awareness related to early screening of cancer are the key factors that augment the market growth.”

Key Findings of the Japan Oncology Drugs Market :



Targeted therapy occupied approximately half share of the Japan oncology drugs market in 2018.

The immunotherapy segment is anticipated to grow with the highest CAGR throughout the forecast period.

The gastrointestinal cancer segment accounted for two-fifth share of the market in 2018.

Lung cancer is anticipated to grow at the highest rate during the analysis period.

Based on indication, the prostate cancer segment occupied the largest share of market in 2018 owing to the presence of huge geriatric population. However, lung cancer segment is expected to show fastest growth during the forecast period attributed to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.

The Japan oncology drugs market is segmented on the basis of drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.

Key Market Players

ABBVIE INC.

Astellas Pharma Inc.

AstraZeneca plc

Bristol-Myers Squibb Company

Celgene Corporation

Daiichi Sankyo Company, Limited

Hoffmann-La Roche AG

Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

Otsuka Holdings Co., Ltd.

Takeda Pharmaceutical Company Ltd.

Request Customization: <https://www.alliedmarketresearch.com/request-for-customization/5642>

FREQUENTLY ASKED QUESTIONS?

Q1. What is the market value of Japan Oncology Drugs Market report in forecast period?

Q2. What would be forecast period in the market report?

Q3. What is the market value of Japan Oncology Drugs Market in 2020?

- Q4. Which is base year calculated in the Japan Oncology Drugs Market report?
- Q5. Does the Japan Oncology Drugs Market company is profiled in the report?
- Q6. Which are the top companies hold the market share in Japan Oncology Drugs Market?
- Q7. Does the Japan Oncology Drugs Market report provides Value Chain Analysis?
- Q8. What are the key trends in the Japan Oncology Drugs Market report?

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

David Correa
Allied Analytics LLP
800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/566077356>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.